Open AccessThis article is
- freely available
HBV and HCV Therapy
“A.M. Migliavacca” Center for Liver Disease, First Gastroenterology Unit, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università di Milano, Via F. Sforza 35, 20122 Milan, Italy
* Author to whom correspondence should be addressed.
Received: 13 August 2009; in revised form: 8 October 2009 / Accepted: 19 October 2009 / Published: 22 October 2009
Abstract: One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.
Keywords: HBV DNA; nucleos(t)ide analogues; Peg-IFN; resistance; HCV RNA; Ribavirin; SVR
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Lampertico, P.; Aghemo, A.; Viganò, M.; Colombo, M. HBV and HCV Therapy. Viruses 2009, 1, 484-509.
Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV Therapy. Viruses. 2009; 1(3):484-509.
Lampertico, Pietro; Aghemo, Alessio; Viganò, Mauro; Colombo, Massimo. 2009. "HBV and HCV Therapy." Viruses 1, no. 3: 484-509.